Xenon Pharmaceuticals Inc. — Director's Dealing 2017

Aug 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2017-08-10

Reporting Person: MORTIMER IAN (CFO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-10	Common Stock	P	5000	$2.845	Acquired	6000	Direct
2017-08-10	Common Stock	P	10000	$2.90	Acquired	14300	Indirect